Keap1-Nrf2 Signaling Pathway-Mediated Antioxidant Defense in Neurodegenerative Diseases: Mechanisms and Traditional Chinese Medicine Therapeutic Strategies
Frontiers in Bioscience-Landmark · 2026-04-17 · 31 (4)
DOI: 10.31083/fbl45233 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience-Landmark, published online on 2026-04-17. Written by Wentao Chen and 7 co-authors. Institution: Yunnan Key Laboratory of Dai and Yi Medicine, Yunnan University of Chinese Medicine, 650500 Kunming, Yunnan, China. Major MEDLINE topics: NF-E2-Related Factor 2, Kelch-Like ECH-Associated Protein 1, Signal Transduction, Neurodegenerative Diseases. 162 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Chinese Medicine, Yunnan Provincial Key Laboratory of Formula Granules.
Abstract (original language)
Neurodegenerative diseases (NDs) are incurable, progressively disabling disorders marked by sustained neuronal degeneration and loss. Their molecular basis involves intricate regulatory networks, while current therapeutic strategies remain inadequate. Oxidative stress (OS) constitutes a major driver in the initiation and progression of age-related pathologies. Kelch-like enoyl-CoA hydratase-associated protein-1 (Keap1)-Nuclear factor Erythroid 2-related factor 2 (Nrf2) signaling pathway, an essential antioxidant system, exerts protective effects by limiting OS-mediated cellular injury. Extensive evidence demonstrates a close association between Nrf2 signaling and the pathological processes of NDs, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS). Traditional Chinese medicine, characterized by multi-target and multi-pathway regulatory actions of its bioactive constituents, offers distinctive therapeutic potential for NDs. This review provides an integrated analysis of current advances of Nrf2 involvement in NDs and evaluates therapeutic strategies based on traditional Chinese medicine and its active components, with the aim of guiding future clinical translation.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Yunnan Key Laboratory of Dai and Yi Medicine, Yunnan University of Chinese Medicine, 650500 Kunming, Yunnan, China.
- College of Ethnic Medicine, Yunnan University of Chinese Medicine, 650500 Kunming, Yunnan, China.
- College of Chinese Medicine, Yunnan University of Chinese Medicine, 650500 Kunming, Yunnan, China.
- College of Basic Medical Sciences, Yunnan University of Chinese Medicine, 650500 Kunming, Yunnan, China.
Funding
- National Natural Science Foundation of China
- Yunnan Provincial Science and Technology Department-Applied Basic Research Joint Special Funds of Chinese Medicine
- Yunnan Provincial Key Laboratory of Formula Granules
- High-level Discipline Construction Project of Dai Medicine, National Administration of Traditional Chinese Medicine
- Yunnan Key Laboratory for Dai and Yi Medicines
Cite
APA
Chen, W., Wang, J., Li, Q., Zhang, L., Wu, X., Luo, S., Xie, Y., & Guo, P. (2026). Keap1-Nrf2 Signaling Pathway-Mediated Antioxidant Defense in Neurodegenerative Diseases: Mechanisms and Traditional Chinese Medicine Therapeutic Strategies. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl45233
Vancouver
Chen W, Wang J, Li Q, Zhang L, Wu X, Luo S, et al. Keap1-Nrf2 Signaling Pathway-Mediated Antioxidant Defense in Neurodegenerative Diseases: Mechanisms and Traditional Chinese Medicine Therapeutic Strategies. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl45233
BibTeX
@article{Chen2026,
author = {Chen, Wentao and Wang, Jiying and Li, Qing and Zhang, Linao and Wu, Xue and Luo, Shifang and Xie, Yuhuan and Guo, Peixin},
title = {Keap1-Nrf2 Signaling Pathway-Mediated Antioxidant Defense in Neurodegenerative Diseases: Mechanisms and Traditional Chinese Medicine Therapeutic Strategies},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {4},
doi = {10.31083/fbl45233}
}
EUVIMED